TP53- mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease

Seyedeh M. Zekavat, Vanesa Viana‐Huete, Saman Doroodgar Jorshery, María A. Zuriaga, Md Mesbah Uddin, Mark Trinder, Kaavya Paruchuri, Nuria Matesanz, Virginia Zorita, Alba Ferrer-Pérez, Marta Amorós-Pérez, Scott M. Damrauer, Christie M. Ballantyne, Abhishek Niroula, Christopher J. Gibson, James P. Pirruccello, Gabriel K. Griffin, Benjamin L. Ebert, Peter Libby, Valentı́n Fuster, Hongyu Zhao, Marzyeh Ghassemi, Pradeep Natarajan, Alexander G. Bick, José J. Fuster, Derek KlarinmedRxiv 2021 · DOI

Abstract

Clonal hematopoiesis of indeterminate potential (CHIP) is a known risk factor for hematologic malignancies and coronary artery disease. However, its role in peripheral artery disease (PAD) and the specific impact of DNA damage repair (DDR) gene mutations, such as TP53, have remained unclear. This study, utilizing data from over 50,000 individuals and mechanistic mouse models, demonstrates that CHIP—particularly when involving DDR genes—significantly increases the risk of incident PAD. Unlike other common CHIP mutations that drive atherosclerosis through inflammation, TP53 mutations promote disease by accelerating macrophage proliferation directly within arterial plaques.

Introduction

As the human body ages, hematopoietic stem cells accumulate somatic mutations. When these mutated cells gain a competitive advantage and expand into a large "clone" of blood cells, the condition is known as Clonal Hematopoiesis of Indeterminate Potential (CHIP). While previous research has established links between CHIP and both blood cancers and coronary artery disease, its influence on the broader vascular system, specifically peripheral artery disease (PAD), has been less understood.

Furthermore, most research has focused on epigenetic regulators like DNMT3A and TET2. This study shifts the focus toward DNA Damage Repair (DDR) genes, such as TP53 and PPM1D. These mutations are of particular clinical interest because they are frequently selected for during cytotoxic chemotherapy, potentially predisposing cancer survivors to accelerated cardiovascular disease.

Methodology

The researchers employed a cross-disciplinary approach to investigate the link between CHIP and PAD:

  1. Human Genomic Analysis: The team analyzed Whole Exome Sequencing (WES) data from 50,122 individuals across the UK Biobank (UKB) and the Mass General Brigham Biobank (MGBB). They identified 2,851 CHIP carriers and used Cox proportional hazards models to assess the risk of incident PAD and atherosclerosis across various arterial beds.
  2. Mechanistic Mouse Models: To establish causality, the researchers performed competitive bone marrow transplantations (BMT) in atherosclerosis-prone Ldlr-/- mice. These "chimeric" mice were engineered to have 20% Trp53-deficient hematopoietic cells, mimicking the human CHIP scenario. The mice were then monitored for plaque development and macrophage accumulation.

Key Findings

Broad Atherosclerotic Risk

The study confirmed that CHIP is a systemic driver of atherosclerosis. Beyond coronary arteries, CHIP was associated with increased risks in the mesenteric arteries and the aorta (including aneurysms). CHIP carriers overall faced a 1.7-fold increased risk for incident PAD (P=2.2×10⁻⁵).

The Potency of DDR Mutations

Mutations in DDR genes carried a significantly higher risk profile. Individuals with DDR CHIP had a 2.0-fold increased risk of PAD. Specifically, TP53 mutations were associated with a nearly five-fold increase in PAD risk (HR 4.98), highlighting the aggressive nature of this specific clonal expansion.

A Unique Pathological Mechanism

A critical discovery of this research is the mechanistic divergence between TP53 and other CHIP mutations. While mutations in genes like TET2 typically drive atherosclerosis through the "inflammasome" (increasing pro-inflammatory cytokines like IL-1β and IL-6), TP53-deficient cells did not show increased expression of these markers in the atherosclerotic aortic wall.

Instead, TP53-deficient macrophages demonstrated a selective proliferative advantage within the arterial wall. In the mouse models, while mutant cells comprised approximately 48% of circulating monocytes, they accounted for ~76% of the macrophages within the plaques. This suggests that the plaque environment specifically favors the expansion of TP53-mutant cells, leading to larger, more cellular plaques.

Clinical Implications and Future Directions

These findings suggest that the cardiovascular risk associated with CHIP is not a monolith. The non-inflammatory nature of TP53-mediated atherosclerosis implies that standard anti-inflammatory therapies (such as those targeting IL-1β) may be ineffective for this specific patient subgroup.

The study also highlights a critical need for specialized cardiovascular surveillance for cancer survivors. Because chemotherapy can select for TP53 and PPM1D clones, patients treated with these agents may face a heightened risk of PAD and other atherosclerotic conditions long after their cancer treatment concludes.

Limitations

The study authors note that the human cohorts were primarily of European ancestry, necessitating further research in more diverse populations. Additionally, the reliance on Electronic Health Record (EHR) billing codes for diagnosis may introduce some misclassification. Future work will focus on identifying therapeutic strategies that can specifically target the proliferative advantage of TP53-mutant macrophages in the vasculature.

Summary updated

Abstract

Abstract Background Somatic mutations in blood indicative of clonal hematopoiesis of indeterminate potential (CHIP), particularly in DNMT3A , TET2 , and JAK2 , are associated with an increased risk of hematologic malignancy, coronary artery disease, and all-cause mortality. However, whether CHIP is associated with increased risk of peripheral artery disease (PAD) remains unknown. In addition, chemotherapy frequently causes mutations in DNA Damage Repair (DDR) genes TP53 and PPM1D , and whether CHIP caused by somatic mutations in DDR genes results in increased risk of atherosclerosis is unclear. We sought to test whether CHIP, and CHIP caused by DDR genes, associates with incident peripheral artery disease (PAD) and atherosclerosis. Methods We identified CHIP among 50,122 exome sequences in individuals from UK and Mass General Brigham Biobanks and tested CHIP status (N=2,851) with incident PAD and atherosclerosis across multiple arterial beds. To mimic the human scenario of clonal hematopoiesis and test whether the expansion of p53-deficient hematopoietic cells contributes to atherosclerosis, a competitive bone marrow transplantation (BMT) strategy was used to generate atherosclerosis-prone Ldlr -/- chimeric mice carrying 20% Trp53 -/- hematopoietic cells (20% KO-BMT mice). We then evaluated aortic plaque burden and plaque macrophage accumulation 12 weeks after grafting. Results CHIP associated with incident PAD (HR 1.7; P=2.2×10 - 5 ) and atherosclerosis in multiple beds (HR 1.3; P=9.7×10 -5 ), with increased risk among individuals with DDR CHIP (HR 2.0; P=0.0084). Among atherosclerosis-prone Ldlr null mice, the p53 -/- 20% KO-BMT mice demonstrated increased aortic plaque size (p=0.013) and accumulation of p53-/- plaque macrophages (P<0.001), driven by an abundance of p53-deficient plaque macrophages. The expansion of p53-deficient cells did not affect the expression of the pro-inflammatory cytokines IL-6 and IL-1β in the atherosclerotic aortic wall. Conclusions Our findings highlight the role of CHIP as a broad driver of atherosclerosis across the entire arterial system, with evidence of increased plaque among p53 -/- 20% KO-BMT mice via expansion of plaque macrophages. These observations provide new insight into the link between CHIP and cardiovascular disease, and lend human genetic support to the concept that post-cytotoxic chemotherapy patients may benefit from surveillance for atherosclerotic conditions in addition to therapy-related myeloid neoplasms.
BibTeX
@misc{zekavat2021i,
  author = {Seyedeh M. Zekavat and Vanesa Viana‐Huete and Saman Doroodgar Jorshery and María A. Zuriaga and Md Mesbah Uddin and Mark Trinder and Kaavya Paruchuri and Nuria Matesanz and Virginia Zorita and Alba Ferrer-Pérez and Marta Amorós-Pérez and Scott M. Damrauer and Christie M. Ballantyne and Abhishek Niroula and Christopher J. Gibson and James P. Pirruccello and Gabriel K. Griffin and Benjamin L. Ebert and Peter Libby and Valentı́n Fuster and Hongyu Zhao and Marzyeh Ghassemi and Pradeep Natarajan and Alexander G. Bick and José J. Fuster and Derek Klarin},
  title = {{<i>TP53-</i> mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease}},
  year = {2021},
  doi = {10.1101/2021.08.22.21262430},
  howpublished = {medRxiv},
}
Figure